We're Leaders in
World Class Medical Research
You can help
Monet Jackson is young but she knows how to win hearts – and how to win out over thalassemia. With your support, there’s no telling what she will accomplish.
Born with thalassemia, Julia Tang has been cured through bone marrow transplantation. Not everyone can benefit from treatments like these – yet. But CAF is making sure that advances continue so that all patients will one day be cured.
The support of people like you makes these advances like these possible. Thank you!
Robert Mannino has been getting blood transfusions since he was six months old. But that hasn’t stopped him from pursuing his dream. Read about this Georgia Tech student (and thalassemia patient)’s use of research to find a better way.
Alyssa Altieri says, without a doubt, that her mom, Sandy is her best friend. Since Alyssa was diagnosed with thalassemia at just five months old, Sandy has been there for her every day.
The Cooley's Anemia Foundation is dedicated to serving people afflicted with various forms of thalassemia, most notably the major form of this genetic blood disease, Cooley's anemia/thalassemia major.
Our mission is advancing the treatment and cure for this fatal blood disease, enhancing the quality of life of patients and educating the medical profession, trait carriers and the public about Cooley's anemia/thalassemia major.
Care Walk is the Cooley’s Anemia Foundation’s annual fundraising event and opportunity to bring together the thalassemia community and its supporters around the country. Funds raised support medical research to fight thalassemia, a genetic blood disorder, as well as patient support services for thalassemia patients across the country. Click here to register for Care Walk!! […]
The FDA has approved Vertex and CRISPR’s gene-editing therapy Casgevy to treat beta thalassemia. Casgevy becomes the first therapy for the rare blood disorder to use the innovative CRISPR gene-editing technology. Vertex Pharmaceuticals and CRISPR Therapeutics have scored an FDA approval for their gene-editing therapy Casgevy (exa-cel) to treat transfusion-dependent beta thalassemia (TDT). The approval […]
Agios Announces Phase 3 ENERGIZE Study of Mitapivat Met Primary Endpoint and Both Key Secondary Endpoints in Adults with Non-Transfusion-Dependent Alpha- or Beta-Thalassemia January 3, 2024 – Agios Pharmaceuticals, Inc. today announced that the global Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary endpoint of […]